stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Shares outstanding
Alnylam Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $134.7M, up 5.51% from $127.7M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $138.0M. Over the past ten years it has ranged from $84.0M (fiscal 2015) to $134.7M (fiscal 2025) — the current reading is the highest in ten years. Alnylam Pharmaceuticals, Inc. ranks 88th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $134.7M | 5.51% |
| FY2024 | $127.7M | 2.20% |
| FY2023 | $124.9M | 2.64% |
| FY2022 | $121.7M | 2.73% |
| FY2021 | $118.5M | 3.01% |
| FY2020 | $115.0M | 5.24% |
| FY2019 | $109.3M | 8.62% |
| FY2018 | $100.6M | 11.08% |
| FY2017 | $90.6M | 5.79% |
| FY2016 | $85.6M | 1.91% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $138.0M | (0.17%) |
| Jun 2026 | $138.3M | 0.04% |
| Mar 2026 | $138.2M | 1.43% |
| Dec 2025 | $136.3M | (0.78%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| EXEL Exelixis, Inc. compare | $255.8M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| INCY Incyte Corporation compare | $203.2M |
| BBIO BridgeBio Pharma, Inc. compare | $196.0M |
| ALNY Alnylam Pharmaceuticals, Inc. | $138.0M |
| ASND Ascendis Pharma A/S compare | $68.3M |
| JAZZ Jazz Pharmaceuticals PLC compare | $64.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement